1 June 2026
Herbert Smith Freehills Kramer advises placing agents on CARsgen Therapeutics’ HK$470 million Hong Kong share placement
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Emsley Lead | Herbert Smith Freehills Kramer | Partner | Not stated | Hong Kong |
| Stanley Xie Lead | Herbert Smith Freehills Kramer | Partner | Not stated | Beijing |
| Jin Kong Lead | Herbert Smith Freehills Kramer | Partner | Not stated | Not stated |
| Maisie Ko | Herbert Smith Freehills Kramer | Not stated | Not stated | Not stated |
| Sean Ji | Herbert Smith Freehills Kramer | Not stated | Not stated | Not stated |
| Crystal Chan | Herbert Smith Freehills Kramer | Not stated | Not stated | Not stated |
| Justin Qiu | Herbert Smith Freehills Kramer | Not stated | Not stated | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- HKD 470m (HK$470 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- CARsgen Therapeutics Holdings Limited (Issuer)
UBS AG Hong Kong Branch (Underwriters)
Macquarie Capital Limited (Underwriters)